BusinessTESARO Announces U.S. FDA Approval of VARUBI® IV for Delayed Nausea and Vomiting Associated With Cancer ChemotherapyBy Nasdaq OMXOct 25, 2017, 11:15 PM UTC
BusinessTESARO Announces Approval of VARUBY® (Oral Rolapitant Tablets) by European CommissionBy Nasdaq OMXApr 26, 2017, 12:31 PM UTC
BusinessTESARO Announces Approval of VARUBY® (Oral Rolapitant Tablets) by European CommissionBy Nasdaq OMXApr 26, 2017, 12:31 PM UTC
BusinessTESARO Outlines Business Priorities and Strategic Outlook for 2016By Nasdaq OMXJan 11, 2016, 1:15 PM UTC
